Literature DB >> 35997276

Fibronectin-EDA accumulates via reduced ubiquitination downstream of Toll-like receptor 9 activation in SSc-ILD fibroblasts.

Ferhan Tuncer1, Melissa Bulik2, John Villandre1,3, Travis Lear1,4, Yanwen Chen1, Beyza Tuncer1, Daniel J Kass3,5, Eleanor Valenzi3,5, Christina Morse2, John Sembrat3, Robert Lafyatis5,2, Bill Chen1,3, John Evankovich1,3.   

Abstract

Accumulation of excessive extracellular matrix (ECM) components from lung fibroblasts is a feature of systemic sclerosis-associated interstitial lung disease (SSc-ILD), and there is increasing evidence that innate immune signaling pathways contribute to these processes. Toll-like receptors (TLRs) are innate immune sensors activated by danger signals derived from pathogens or host molecular patterns. Several damage-associated molecular pattern (DAMP) molecules are elevated in SSc-ILD plasma, including ligands that activate TLR9, an innate immune sensor recently implicated in driving profibrotic responses in fibroblasts. Fibronectin and the isoform fibronectin-extra domain A (FN-EDA) are prominent in pathological extracellular matrix accumulation, but mechanisms promoting FN-EDA accumulation are only partially understood. Here, we show that TLR9 activation increases FN-EDA accumulation in MRC5 and SSc-ILD fibroblasts, but that this effect is independent of changes in FN-EDA gene transcription. Rather, we describe a novel mechanism where TLR9 activation inhibits FN-EDA turnover via reduced FN-EDA ubiquitination. TLR9 ligand ODN2006 reduces ubiquitinated FN-EDA destined for lysosomal degradation, an effect abrogated with TLR9 knockdown or inhibition. Taken together, these results provide rationale for disrupting the TLR9 signaling axis or FN-EDA degradation pathways to reduce FN-EDA accumulation in SSc-ILD fibroblasts. More broadly, enhancing intracellular degradation of ECM components through TLR9 inhibition or enhanced ECM turnover could be a novel strategy to attenuate pathogenic ECM accumulation in SSc-ILD.

Entities:  

Keywords:  Toll-like receptor 9; fibronectin; systemic sclerosis

Mesh:

Substances:

Year:  2022        PMID: 35997276      PMCID: PMC9550569          DOI: 10.1152/ajplung.00019.2022

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   6.011


  35 in total

1.  Changes in causes of death in systemic sclerosis, 1972-2002.

Authors:  Virginia D Steen; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

Review 2.  Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies.

Authors:  Nicole Fett
Journal:  Clin Dermatol       Date:  2013 Jul-Aug       Impact factor: 3.541

3.  Poly(I:C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis.

Authors:  Giuseppina A Farina; Michael R York; Michael Di Marzio; Cindy A Collins; Stephan Meller; Bernhard Homey; Ian R Rifkin; Ann Marshak-Rothstein; Timothy R D J Radstake; Robert Lafyatis
Journal:  J Invest Dermatol       Date:  2010-07-08       Impact factor: 8.551

Review 4.  Novel insights on the role of the innate immune system in systemic sclerosis.

Authors:  Michael R York
Journal:  Expert Rev Clin Immunol       Date:  2011-07       Impact factor: 4.473

5.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.

Authors:  Anthony J Tyndall; Bettina Bannert; Madelon Vonk; Paolo Airò; Franco Cozzi; Patricia E Carreira; Dominique Farge Bancel; Yannick Allanore; Ulf Müller-Ladner; Oliver Distler; Florenzo Iannone; Raffaele Pellerito; Margarita Pileckyte; Irene Miniati; Lidia Ananieva; Alexandra Balbir Gurman; Nemanja Damjanov; Adelheid Mueller; Gabriele Valentini; Gabriela Riemekasten; Mohammed Tikly; Laura Hummers; Maria J S Henriques; Paola Caramaschi; Agneta Scheja; Blaz Rozman; Evelien Ton; Gábor Kumánovics; Bernard Coleiro; Eva Feierl; Gabriella Szucs; Carlos Alberto Von Mühlen; Valeria Riccieri; Srdan Novak; Carlo Chizzolini; Anna Kotulska; Christopher Denton; Paulo C Coelho; Ina Kötter; Ismail Simsek; Paloma García de la Pena Lefebvre; Eric Hachulla; James R Seibold; Simona Rednic; Jirí Stork; Jadranka Morovic-Vergles; Ulrich A Walker
Journal:  Ann Rheum Dis       Date:  2010-06-15       Impact factor: 19.103

Review 6.  Innate Immunity in Systemic Sclerosis.

Authors:  Christopher Dowson; Nathan Simpson; Laura Duffy; Steven O'Reilly
Journal:  Curr Rheumatol Rep       Date:  2017-01       Impact factor: 4.592

Review 7.  Assembly of fibronectin extracellular matrix.

Authors:  Purva Singh; Cara Carraher; Jean E Schwarzbauer
Journal:  Annu Rev Cell Dev Biol       Date:  2010       Impact factor: 13.827

8.  TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis.

Authors:  Glenda Trujillo; Alessia Meneghin; Kevin R Flaherty; Lynette M Sholl; Jeffrey L Myers; Ella A Kazerooni; Barry H Gross; Sameer R Oak; Ana Lucia Coelho; Holly Evanoff; Elizabeth Day; Galen B Toews; Amrita D Joshi; Matthew A Schaller; Beatrice Waters; Gabor Jarai; John Westwick; Steven L Kunkel; Fernando J Martinez; Cory M Hogaboam
Journal:  Sci Transl Med       Date:  2010-11-10       Impact factor: 17.956

9.  Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo.

Authors:  Glenn A McDonald; Pradip Sarkar; Helmut Rennke; Elaine Unemori; Raghu Kalluri; Vikas P Sukhatme
Journal:  Am J Physiol Renal Physiol       Date:  2003-07

10.  TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung.

Authors:  Swati Bhattacharyya; Wenxia Wang; Wenyi Qin; Kui Cheng; Sara Coulup; Sherry Chavez; Shuangshang Jiang; Kirtee Raparia; Lucia Maria V De Almeida; Christian Stehlik; Zenshiro Tamaki; Hang Yin; John Varga
Journal:  JCI Insight       Date:  2018-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.